A preservative-free version of Lumigan gel led to IOP reductions comparable to a preserved version of the ophthalmic solution, with a lower rate of treatment-related ocular adverse events.
The study, published in Journal of Glaucoma, demonstrated the noninferiority of a preservative-free gel form of Lumigan (bimatoprost 0.01%, AbbVie), which has not been approved in the U.S.
“Chronic exposure to preservative-containing eye drops has been associated with the exacerbation of ocular surface disease,” Eydie G. Miller-Ellis, MD, of Scheie Eye Institute at University of Pennsylvania, and